Acute, chronic and withdrawal effects of the cannabinoid receptor agonist WIN55212-2 on the sequential activation of MAPK/Raf-MEK-ERK signaling in the rat cerebral frontal cortex: Short-term regulation by intrinsic and extrinsic pathways

Journal of Neuroscience Research

Volumn 85, Issue 3, 2007, Pages 656-667

  Moranta, David ^a   Esteban, Susana ^a   García Sevilla, Jesús A ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

CB1 receptors; MEK inhibition (SL327); NMDA blockade (MK801); Raf MEK ERK activity; Rat brain; WIN55212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RIMONABANT; SL 327; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FRONTAL CORTEX; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; WITHDRAWAL REFLEX; WITHDRAWAL SYNDROME;

ANIMALS; BENZOXAZINES; CANNABINOIDS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FRONTAL LOBE; MALE; MAP KINASE KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; NAPHTHALENES; RAF KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION;

EID: 33847291794     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21140     Document Type: Article

References (64)

1. Aceto MD, Scates SM, Martin BB. 2001. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. Eur J Pharmacol 416:75-81.
2. Ameri A. 1999. The effects of cannabinoids on the brain. Prog Neurobiol 58:315-348.
3. Asensio VJ, Miralles A, García-Sevilla JA. 2006. Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by μ-, δ- and κ-opioid receptor agonists in the rat brain: Regulation by chronic morphine and opioid withdrawal. Eur J Pharmacol 539:49-56.
4. Baker D, Pryce G, Davies WL, Hiley CR. 2006. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27:1-4.
5. 1 receptor and group II metabotropic glutamate receptor signalling in layer V pyramidal neurons from the rat prefrontal cortex. Eur J Neurosci 17:981-990.
6. Cannizzaro C, D'Amico M, Preziosi P, Martire M. 2006. Presynaptic effects of anandamide and WIN55,212-2 on glutamatergic nerve endings isolated from rat hippocampus. Neurochem Int 48:159-165.
7. Cao J-L, He J-H, Ding H-L, Zeng Y-M. 2005. Activation of the spinal ERK signaling pathway contributes naloxone-precipitated withdrawal in morphine-dependent rats. Pain 118:336-349.
8. Castañé A, Maldonado R, Valverde O. 2004. Role of different brain structures in the behavioural expression of WIN 55, 212-2 withdrawal in mice. Br J Pharmacol 142:1309-1317.
9. Crossthwaite AJ, Valli H, Williams RJ. 2004. Inhibiting Src family tyrosine kinase activity blocks glutamate signalling to ERK1/2 and Akt/PKB but not JNK in cultured striatal neurones. J Neurochem 88:1127-1139.
10. Demuth DG, Molleman A. 2006. Cannabinoid signalling. Life Sci 78:549-563.
11. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C, Trzaskos J, Caboche J, Girault JA. 2003. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 23:2371-2382.
12. Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt HU, Zieglgansberger W, Lutz B, Rammes G. 2006. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci 26:5794-5799.
13. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, Morrison DK. 2005. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 17:215-224.
14. 1 receptor mediated c-Jun N-terminal kinase activation in cultured cortical neurons. Br J Pharmacol 140:547-557.
15. Egerton A, Allison C, Brett RR, Pratt JA. 2006. Cannabinoids and prefrontal cortical function: Insights from preclinical studies. Neurosci Biobehav Rev 30:680-695.
16. Ellert-Miklaszewska A, Kaminska B, Konarska L. 2005. Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal 17:25-37.
17. Ferguson SM, Robinson TE. 2004. Amphetamine-evoked gene expression in striatopallidal beurons: regulation by corticostriatal afferents andthe ERK/MAPK signaling cascade. J Neurochem 91:337-348.
18. Ferrer-Alcón M, García-Fuster MJ, La Harpe R, García-Sevilla JA. 2004. Long-term regulation of signalling components of adenyl cyclase and mitogen-activated protein kinase in the pre-frontal cortex of human opiate addicts. J Neurochem 90:220-230.
19. Fujioka A, Terai K, Itoh RE, Aoki K, Nakamura T, Kuroda S, Nishida E, Matsuda M. 2006. Dynamics of the Ras/ERK MAPK cascade as monitored by fluorescent probes. J Biol Chem 281:8917-8926.
20. García-Fuster MJ, Miralles A, García-Sevilla JA. 2006. Effects of opiate drugs on Fas-associated protein with death domain (FADD) and effector caspases in the rat brain: Regulation by the ERK1/2 MAP kinase pathway. Neuropsychopharmacology(in press) [doi 10.1038/sj.npp.1301040].
21. Glass M, Dragunow M, Faull RL. 1997. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299-318.
22. Grewal SS, York RD, Stork PJS. 1999. Extracellular signal-regulated kinase signalling in neurons. Curr Opin Neurobiol 9:544-553.
23. Guzmán M. 2003. Neurons on cannabinoids: dead or alive? Br J Pharmacol 140:439-440.
24. Hájos N, Ledent C, Freund TF. 2001. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106:1-4.
25. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de-Costa BR, Rice KC. 1991. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
26. Hornberg JJ, Binder B, Bruggeman FJ, Schoebert B, Heinrich R, Westerhoff HV. 2005. Control of MAPK signalling: from complexity to what really matters. Oncogene 24:5533-5542.
27. Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, Maldonado R. 1998. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 125:1567-1577.
28. Janoyan JJ, Crim JL, Darmani NA. 2002. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids. Pharmacol Biochem Behav 71:155-162.
29. Kolb B, Gorny G, Limebeer CL, Parker LA. 2006. Chronic treatment with Δ-9-tetrahydrocannabinol alters the structure of neurons in the nucleus accumbens shell and medial prefrontal cortex of rats. Synapse 60:429-436.
30. Koob GF, Sanna PP, Bloom FE. 1998. Neuroscience of addiction. Neuron 21:467-476.
31. Krapivinsky G, Krapivinsky L, Manasian Y, Ivanov A, Tyzio R, Pellegrino C, Ben-Ari Y, Clapham DE, Medina I. 2003. The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1. Neuron 40:775-784.
32. Lichtman AH, Martin BR. 2005. Cannabinoid tolerance and dependence. In: Pertwee R, editor. Cannabinoids. Hdbk Exp Pharmacol 168. New York: Springer-Verlag. p 691-717.
33. Lu L, Hope BT, Dempsey J, Liu SY, Bossert JM, Shaham Y. 2005. Central amygdala ERK signaling pathway is critical to incubation of cocaine craving. Nat Neurosci 8:212-219.
34. Maldonado R, Valverde O, Berrendero F. 2006. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29:225-232.
35. Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R. 1999. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBOJ 18:2137-2148.
36. 3H]glutamate-binding sites in rat brain. J Neurosci 5: 2909-2919.
37. 1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn-Schmiedebergs Arch Pharmacol 369:516-524.
38. 1 receptors in rat frontal cortex. Methods Find Exp Clin Pharmacol 27(Suppl 2):119.
39. 2+ signals in cerebellar granule nuerons in culture. J Neurosci 19:8765-8777.
40. Olmos G, Ribera J, García-Sevilla JA. 1996. Imidazoli(di)ne compounds interact with the phencyclidine site of NMDA receptors in the rat brain. Eur J Pharmacol 310:273-276.
41. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. 2001. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22:153-183.
42. 2 receptors. Pharmacol Ther 74:129-180.
43. Pertwee RG. 2006. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147:S163-S171.
44. Powles T, Poele R, Shamash J, Chapin T, Propper D, Joel S, Oliver T, Liu WM. 2005. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 105:1214-1221.
45. Robinson FL, Whitehurst AW, Raman M, Coob MH. 2002. Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1. J Biol Chem 277:14844-14852.
46. Rubino T, Forlani G, Viganò D, Zippel R, Parolaro D. 2004. Modulation of extracellular signal-regulated kinase cascade by chronic delta 9-tetrahydrocannabinol treatment. Mol Cell Neurosci 25:355-362.
47. Rubino T, Forlani G, Viganò D, Zippel R, Parolaro D. 2005. Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects. J Neurochem 93:984-991.
48. Sanna PP, Simpson C, Lutjens R, Koob G. 2002. ERK regulation in chronic ethanol exposure and withdrawal. Brain Res 948:186-191.
49. Scherle PA, Ma W, Lim H, Dey SK, Trzaskos JM. 2000. Regulation of cyclooxygenase-2 induction in the mouse uterus during decidualization. J Biol Chem 275:37086-37092.
50. Schmeling WT, Hosko MJ. 1980. Effect of delta 9-tetrahydrocannabinol on hypothalamic termosensitive units. Brain Res 187:431-442.
51. Schultz S, Höllt V. 1998. Opioid withdrawal activates MAP kinase in locus coeruleus neurons in morphine-dependent rats in vivo. Eur J Neurosci 10:1196-1201.
52. 1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15:91-119.
53. 1 rceptor adaptation after cessation of long-term cannabinoid administration. Mol Pharmacol 70:986-996.
54. Tanda G, Goldberg SR. 2003. Cannabinoids: reward, dependence, and underlying mechanisms - a review of recent preclinical data. Psychopharmacology 169:115-134.
55. Tonini R, Ciardo S, Cerovic M, Rubino T, Parolaro D, Mazzanti M, Zippel R. 2006. ERK-dependent modulation of cerebellar synaptic plasticity after chronic delta9-tetrahydrocannabinol exposure. J Neurosci 26:5810-5818.
56. Trakul N, Rosner MR. 2005. Modulation of the MAP kinase signaling cascade by Raf kinase inhibitory protein. Cell Res 15:19-23.
57. Troppmair J, Rapp UR. 2003. Raf and the road to cell survival: a tale of bad spells, ring bearers and detours. Biochem Pharmacol 66:1341-1345.
58. Valjent E, Pages C, Rogard M, Besson MJ, Maldonado R, Caboche J. 2001. Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. Eur J Neurosci 14:342-352.
59. Valjent E, Pages C, Herve D, Girault JA, Caboche J. 2004. Addictive and nonaddictive drugs induce distinct and specific patterns of ERK activation in mouse brain. Eur J Neurosci 19:1826-1836.
60. Valjent E, Corvol J-C, Trzaskos JM, Girault A, Hervé D. 2006. Role of the ERK pathway in psychostimulant-induced locomotor sensitization. BMC Neurosci 7:20[doi 10.1186/1471-2202-7-20].
61. Valverde O, Maldonado R, Valjent F, Zimmer AM, Zimmer A. 2000. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci 20:9284-9289.
62. Vogel S, Kubin T, von der Ahe D, Deindl E, Schaper W, Zimmermann R. 2006. MEK hyperphosphorylation coincides with cell cycle shut down of cultiured smooth muscle cells. J Cell Physiol 206:25-34.
63. Wellbrock C, Karasarides M, Marais R. 2004. The Raf proteins take centre stage. Nat Rev Mol Cell Biol 5:875-885.
64. Yoon S, Seger R. 2006. The extracellular signal-regulated kinase: multiple susbtrates regulate diverse cellular functions. Growth Fact 24:21-44.